ST Phi Therapeutics
Seattle, US · Founded 2017 · Delaware corporation · 1 known investors
Founders & leadership
LL
Lingfeng LiuNamed on SEC filing
XG
Xiaobin GuoNamed on SEC filing
Investors · 1
Reported raises · per SEC filings
Form D private placements$500K disclosed across 1 round · 2018
▶$500KraisedJan 2018 · 1 investors · BiotechnologyRule 506(b)
▶$500KraisedJan 2018 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Lingfeng LiuExecutive Officer, Director
- Xiaobin GuoExecutive Officer, Director
- Offering amount
- $500K
- Amount sold
- $500K
- First sale
- Jan 2018
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- Who are ST Phi Therapeutics's investors?
- ST Phi Therapeutics's investors include Panacea Venture.
- How much funding has ST Phi Therapeutics raised?
- ST Phi Therapeutics has disclosed $500K raised across 1 round.
- Where is ST Phi Therapeutics headquartered?
- ST Phi Therapeutics is headquartered in Seattle, US.